Immune evasion by Kaposi's sarcoma-associated herpesvirus
- PMID: 17457345
- DOI: 10.1038/nri2076
Immune evasion by Kaposi's sarcoma-associated herpesvirus
Abstract
To efficiently establish a persistent infection, Kaposi's sarcoma-associated herpesvirus (KSHV; also known as HHV8) dedicates a large amount of its coding potential to produce proteins that antagonize the immune system of its host. These viral immunomodulators interfere with both the innate and adaptive immune responses and most of them are homologous to cellular proteins, suggesting that they have been pirated from the host during viral evolution. In this Review, I present recent advances in the understanding of immune evasion by KSHV, with a particular focus on the virally encoded modulators of immune responses that are unique to this virus.
Similar articles
-
Molecular virology of Kaposi's sarcoma-associated herpesvirus.Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516. doi: 10.1098/rstb.2000.0777. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11313008 Free PMC article. Review.
-
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.AIDS. 2007 Jun 19;21(10):1245-52. doi: 10.1097/QAD.0b013e328182df03. AIDS. 2007. PMID: 17545700 Clinical Trial.
-
Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis.AIDS Rev. 2003 Oct-Dec;5(4):222-9. AIDS Rev. 2003. PMID: 15012001 Review.
-
Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease.Pathol Int. 2006 Oct;56(10):617-24. doi: 10.1111/j.1440-1827.2006.02017.x. Pathol Int. 2006. PMID: 16984619
-
The pleiotropic effects of Kaposi's sarcoma herpesvirus.J Pathol. 2006 Jan;208(2):187-98. doi: 10.1002/path.1904. J Pathol. 2006. PMID: 16362980 Review.
Cited by
-
Multicentric Castleman disease and the evolution of the concept.Pathologica. 2021 Oct;113(5):339-353. doi: 10.32074/1591-951X-351. Pathologica. 2021. PMID: 34837092 Free PMC article. Review.
-
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.J Virol. 2015 Nov 4;90(3):1158-68. doi: 10.1128/JVI.01392-15. Print 2016 Feb 1. J Virol. 2015. PMID: 26537687 Free PMC article.
-
Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.J Virol. 2015 Aug;89(15):7874-92. doi: 10.1128/JVI.00895-15. Epub 2015 May 20. J Virol. 2015. PMID: 25995248 Free PMC article.
-
Silencing viral microRNA as a novel antiviral therapy?J Biomed Biotechnol. 2009;2009:419539. doi: 10.1155/2009/419539. Epub 2009 May 28. J Biomed Biotechnol. 2009. PMID: 19704916 Free PMC article. Review.
-
Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter.J Biol Chem. 2010 Mar 5;285(10):7208-21. doi: 10.1074/jbc.M109.018838. Epub 2010 Jan 4. J Biol Chem. 2010. PMID: 20048166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources